Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma-Reference-Cited by-同舟云学术

Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma

Published:2014-04 Issue:2 Volume:12 Page:130-137
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Agarwal Neeraj,Bellmunt Joaquim,Maughan Benjamin L.,Boucher Kenneth M.,Choueiri Toni K.,Qu Angela Q.,Vogelzang Nicholas J.,Fougeray Ronan,Niegisch Guenter,Albers Peter,Wong Yu-Ning,Ko Yoo-Joung,Sridhar Srikala S.,Tantravahi Srinivas K.,Galsky Matthew D.,Petrylak Daniel P.,Vaishampayan Ulka N.,Mehta Amitkumar N.,Beer Tomasz M.,Sternberg Cora. N.,Rosenberg Jonathan E.,Sonpavde Guru

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference20 articles.

1. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study;Saxman;J Clin Oncol,1997

2. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours;Sternberg;Eur J Cancer,2006

3. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J Clin Oncol,2000

4. Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy;Beer;Clin Genitourin Cancer,2008

5. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer;Choueiri;J Clin Oncol,2012

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1);British Journal of Cancer;2023-12-15

2. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework;Health Technology Assessment;2021-12

3. Ramucirumab as a Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: A Meta-Analysis of Randomized Clinical Trials;ECB 2021;2021-05-31

4. A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer;British Journal of Cancer;2020-09-11

5. Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer;Critical Reviews in Oncology/Hematology;2018-10